CAMBRIDGE, Mass. and EXTON, Pa., March 03, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera’s Chief Executive Officer, Vincent Milano will present at the Cowen and Company 36th Annual Healthcare Conference on Monday, March 7, 2016 at 4:00 p.m. Eastern Time at the Marriott Copley Place in Boston.
The company is also announcing that Louis Arcudi, Idera’s Chief Financial Officer will present at the 28th Annual Roth Conference on Monday, March 14, 2016 at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time). The conference is being held at the Ritz Carlton in Dana Point, CA.
Live audio webcast of Idera’s presentations will be accessible in the Investors and Media section of Idera’s website at http://www.iderapharma.com. Archived versions will also be available on the Company’s website after the event for 90 days. A copy of Idera’s slide presentation will be posted to the Investor’s section of the corporate website on Monday, March 7, 2016.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.
Investor and Media Contact Robert Doody VP, IR & Corporate Communications 617-679-5515 (office) 484‐639‐7235 (mobile) firstname.lastname@example.org
Source:Idera Pharmaceuticals, Inc.